MACH7 TECHNOLOGIES LIMITED (M7T)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:

M7T - MACH7 TECHNOLOGIES LIMITED
FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.72
Index:
Mach7 Technologies develops software platforms for the healthcare industry. It specialises in image management systems and patient data management. The company has been listed on the ASX since 2005.
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$0.73
21 Sep |
OPEN $0.73 |
HIGH $0.74 |
7,379 LOW $0.72 |
TARGET | |||||
|
OTHER COMPANIES IN THE SAME SECTOR | |||
ACL . AHX . ALC . BMT . CAJ . DOC . EBO . HLA . HLS . MDR . MPL . MVF . NHF . PSQ . RHC . SHL . SLA . |
FNARENA'S MARKET CONSENSUS FORECASTS
Title | FY22 Actual |
FY23 Actual |
FY24 Forecast |
FY25 Forecast |
---|---|---|---|---|
EPS (cps) | xxx | - 0.4 | - 0.5 | xxx |
DPS (cps) | xxx | 0.0 | 0.0 | xxx |
EPS Growth | xxx | N/A | N/A | xxx |
DPS Growth | xxx | N/A | N/A | xxx |
PE Ratio | xxx | N/A | N/A | xxx |
Dividend Yield | xxx | N/A | 0.0% | xxx |
Div Pay Ratio(%) | xxx | N/A | N/A | xxx |
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | -0.4 |
DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 30.0 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 24.8 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -2.6 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -3.49 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -1.78 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -1.75 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | -1.30 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | -1.78 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -11.66 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -3.0 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 0 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | 1 M |
Total Debt | xxx | xxx | xxx | xxx | xxx | 1 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | 4 M |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 23 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | 2.50 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 0.4 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 1.20 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 31 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 6 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | - |
Investments - Total | xxx | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
M7T STOCK CHART

FNArena News on M7T
1 |
FNArena Corporate Results Monitor – 01-09-2023Sep 01 2023 - Australia |
2 |
In Brief: Healthcare, Travel, Technology, Housing & US Debt DowngradeAug 04 2023 - Weekly Reports |
3 |
Australian Broker Call *Extra* Edition – Mar 15, 2023Mar 15 2023 - Daily Market Reports |
4 |
FNArena Corporate Results Monitor – 01-03-2023Mar 01 2023 - Australia |
5 |
Australian Broker Call *Extra* Edition – Feb 02, 2023Feb 02 2023 - Daily Market Reports |
Latest Healthcare services News
1 |
Timing Seems Right For Alcidion GroupJun 21 2023 - Small Caps |
2 |
No Enthusiasm To Combine ACL & HealiusMar 21 2023 - Australia |
3 |
Dr Boreham’s Crucible: AlcidionDec 13 2022 - Small Caps |
4 |
No Straight Covid-Relief For Ramsay Health CareNov 15 2022 - Australia |
5 |
Dr Boreham’s Crucible: Mach7 TechnologiesNov 14 2022 - Small Caps |
6 |
Negative Industry Trends Impact Australian Clinical LabsAug 12 2022 - Small Caps |
7 |
Healius Offers Digital Carrot, Base Remains SoftMay 25 2022 - Australia |
8 |
Ramsay Stakes Future on Mental HealthDec 20 2021 - Australia |
9 |
Ramsay Health Care: Finally A Break-OutNov 09 2021 - Technicals |
10 |
Funding Overhang Weighs On Ramsay’s ReboundJun 10 2021 - Australia |